Pharmaceutical spin-off AbbVie recently received a big upgrade from Wall Street bank Morgan Stanley, sending shares up 6% last week. In this video, health-care analyst David Williamson breaks down what investors need to know about this bullish report, and why they might want to show caution before buying AbbVie stock.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Breaking Down AbbVie's Big Upgrade
By Dave Williamson
–
Apr 28, 2013 at 4:00PM
NYSE: ABBV
AbbVie
Market Cap
$340B
Today's Change
(-0.48%) -$0.93
Current Price
$191.52
Price as of July 14, 2025, 3:58 p.m. ET
Shares soared after a bullish report from investment bank Morgan Stanley, but is it time to buy?
David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.
The Motley Fool recommends Gilead Sciences. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
AbbVie
ABBV
$191.52
(-0.48%)
$0.93
Pfizer
PFE
$25.35
(-1.17%)
$0.30
Gilead Sciences
GILD
$112.14
(2.28%)
$2.50
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
3 Dividend Growth Stocks to Buy and Hold
3 No-Brainer Stocks to Buy in July
2 Dividend Stocks to Buy for Decades of Passive Income
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
3 Dividend Stocks to Double Up on Right Now
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.